Stockscreener 앱 받기
2.4041
3.53%
0.0841
Allurion Technologies Inc 주식(ALUR)의 최신 뉴스
Major Weight Loss Breakthrough: 20,000 Patient Study Reveals Muscle-Preserving Success of Allurion Program - Stock Titan
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS - New Castle News
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Down 42.4% in May - Defense World
(ALUR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Allurion Technologies (NYSE:ALUR) Trading 2.1% Higher – Time to Buy? - Defense World
Allurion at Jefferies Conference: Strategic US Market Entry By Investing.com - Investing.com South Africa
Allurion at Jefferies Conference: Strategic US Market Entry - Investing.com Australia
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - The Globe and Mail
Allurion to Present at Jefferies Global Healthcare Conference - BioSpace
When the Price of (ALUR) Talks, People Listen - news.stocktradersdaily.com
ALURALLURION TECHNOLOGIES INC Latest Stock News & Market Updates - Stock Titan
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results - MSN
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program - BioSpace
Allurion Weight Loss Program Builds Muscle Mass 6.6%, Cuts Fat 11% in Clinical Study | ALUR Stock News - Stock Titan
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
4 Medical Product Stocks to Watch From a Challenging Industry - Yahoo Finance
Trend Tracker for (ALUR) - news.stocktradersdaily.com
Research Analysts Offer Predictions for ALUR FY2025 Earnings - Defense World
Yale University's Strategic Exit from Allurion Technologies Inc: A 13F Filing Insight - GuruFocus
Allurion Technologies Earnings Call: Transition and Growth - TipRanks
Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025 - MSN
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates - MSN
Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Allurion Technologies Reports Q1 2025 Financial Results - TipRanks
Allurion Technologies (ALUR) Unveils Promising Obesity Treatment Results | ALUR Stock News - GuruFocus
Allurion Technologies (ALUR) Q1 2025 Results Highlight Revenue a - GuruFocus
Transcript : Allurion Technologies Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
What To Expect From Allurion Technologies Inc (ALUR) Q1 2025 Ear - GuruFocus
Allurion To File Final Module Of Weight Loss Balloon To FDA For Approval Next Month - Nasdaq
Allurion Technologies (ALUR) Surges Over 50% Following Data Pres - GuruFocus
Earnings call transcript: Allurion Technologies Q1 2025 sees revenue drop, stock surges - Investing.com
Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript - MSN
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Prom - GuruFocus
Allurion Technologies Q1 2025 Financial Results - TradingView
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Promising Year | ALUR Stock News - GuruFocus
Allurion Technologies reports Q1 EPS 20c vs. ($2.78) last year - TipRanks
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
After-Market Rally For Allurion (ALUR) As New Data Sparks Investor Optimism - Stocks Telegraph
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss - 01net
Allurion reports weight loss breakthrough at obesity congress - Investing.com Australia
Allurion reports weight loss breakthrough at obesity congress By Investing.com - Investing.com Nigeria
New Clinical Data: Allurion's Swallowable Balloon Supercharges GLP-1 Weight Loss Results, Preserves Muscle - Stock Titan
0.42%
0.11%
자본화:
|
볼륨(24시간):